Given its crucial role in DNA repair, RAD51 is a potential target for cancer therapy. Inhibitors of RAD51 can sensitize cancer cells to treatments by preventing them from repairing induced DNA damage. This approach is particularly useful in cancers with defects in other DNA repair pathways, such as those involving BRCA1 or BRCA2.
